Huizinga Robert Bindert
SEC CIK 1837648 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| AUPH | Aurinia Pharmaceuticals Inc. | EVP of Research | 69.4K | — | $5.48M | 8 | 2021-09-07 | 2022-03-02 |
Most active insiders at AUPH, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | TANG KEVIN | Dir | $25.14M | — |
| 2 | Robertson Stephen P. | EVP, GC | — | $546.4K |
| 3 | Cole Ryan | COO | — | — |
| 4 | Keenan Greg | SVP, Chief Medical Off | — | — |
| 5 | Hearne Michael S | CFO | — | — |
| 6 | Miller Joseph M | CFO | — | — |
| 7 | Donley Matthew Maxwell | COO | — | — |
| 8 | Bailey Jeffrey Allen | Dir | — | — |
| 9 | Johnson Craig A | Dir | — | — |
| 10 | Greenleaf Peter | CEO, Dir | — | — |
Huizinga Robert Bindert made no open-market trades at AUPH in the last 12 months.
Transactions 8
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-04 | 2022-03-02 | AUPH | Aurinia Pharmaceuticals Inc. | Huizinga Robert Bindert | EVP of Research | S - Sale | $12.01 | -4,849 | 69.4K | -7% | -$58.2K |
| D | 2022-03-04 | 2022-03-02 | AUPH | Aurinia Pharmaceuticals Inc. | Huizinga Robert Bindert | EVP of Research | A - Grant | $0.00 | +8,500 | 74.2K | +13% | $0 |
| D | 2021-10-26 | 2021-10-25 | AUPH | Aurinia Pharmaceuticals Inc. | Huizinga Robert Bindert | EVP of Research | M - OptEx | $3.20 | +95.0K | 195.7K | +94% | +$304.0K |
| D | 2021-10-26 | 2021-10-25 | AUPH | Aurinia Pharmaceuticals Inc. | Huizinga Robert Bindert | EVP of Research | S - Sale+OE | $29.75 | -130.0K | 65.7K | -66% | -$3.87M |
| DM | 2021-09-22 | 2021-09-21 | AUPH | Aurinia Pharmaceuticals Inc. | Huizinga Robert Bindert | EVP of Research | S - Sale+OE | $23.99 | -32.5K | 100.7K | -24% | -$779.5K |
| DM | 2021-09-22 | 2021-09-21 | AUPH | Aurinia Pharmaceuticals Inc. | Huizinga Robert Bindert | EVP of Research | M - OptEx | $2.86 | +27.1K | 122.1K | +29% | +$77.7K |
| M | 2021-09-14 | 2021-09-10+ | AUPH | Aurinia Pharmaceuticals Inc. | Huizinga Robert Bindert | EVP of Research | S - Sale | $21.15 | -32.5K | 106.1K | -23% | -$687.3K |
| 2021-09-08 | 2021-09-07 | AUPH | Aurinia Pharmaceuticals Inc. | Huizinga Robert Bindert | EVP of Research | S - Sale | $18.30 | -5,000 | 138.6K | -3% | -$91.5K |
Purchase Sale Sale after option exercise All abbreviations